PMID- 27822209
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 7
DP  - 2016
TI  - Antibody Subclass Repertoire and Graft Outcome Following Solid Organ 
      Transplantation.
PG  - 433
LID - 433
AB  - Long-term outcomes in solid organ transplantation are constrained by the 
      development of donor-specific alloantibodies (DSA) against human leukocyte 
      antigen (HLA) and other targets, which elicit antibody-mediated rejection (ABMR). 
      However, antibody-mediated graft injury represents a broad continuum, from 
      extensive complement activation and tissue damage compromising the function of 
      the transplanted organ, to histological manifestations of endothelial cell injury 
      and mononuclear cell infiltration but without concurrent allograft dysfunction. 
      In addition, while transplant recipients with DSA as a whole fare worse than 
      those without, a substantial minority of patients with DSA do not experience 
      poorer graft outcome. Taken together, these observations suggest that not all DSA 
      are equally pathogenic. Antibody effector functions are controlled by a number of 
      factors, including antibody concentration, antigen availability, and antibody 
      isotype/subclass. Antibody isotype is specified by many integrated signals, 
      including the antigen itself as well as from antigen-presenting cells or helper T 
      cells. To date, a number of studies have described the repertoire of IgG 
      subclasses directed against HLA in pretransplant patients and evaluated the 
      clinical impact of different DSA IgG subclasses on allograft outcome. This review 
      will summarize what is known about the repertoire of antibodies to HLA and 
      non-HLA targets in transplantation, focusing on the distribution of IgG 
      subclasses, as well as the general biology, etiology, and mechanisms of injury of 
      different humoral factors.
FAU - Valenzuela, Nicole M
AU  - Valenzuela NM
AD  - UCLA Immunogenetics Center, University of California Los Angeles, Los Angeles, 
      CA, USA; Department of Pathology and Laboratory Medicine, David Geffen School of 
      Medicine, University of California Los Angeles, Los Angeles, CA, USA.
FAU - Hickey, Michelle J
AU  - Hickey MJ
AD  - UCLA Immunogenetics Center, University of California Los Angeles, Los Angeles, 
      CA, USA; Department of Pathology and Laboratory Medicine, David Geffen School of 
      Medicine, University of California Los Angeles, Los Angeles, CA, USA.
FAU - Reed, Elaine F
AU  - Reed EF
AD  - UCLA Immunogenetics Center, University of California Los Angeles, Los Angeles, 
      CA, USA; Department of Pathology and Laboratory Medicine, David Geffen School of 
      Medicine, University of California Los Angeles, Los Angeles, CA, USA.
LA  - eng
GR  - R56 AI042819/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20161024
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5075576
OTO - NOTNLM
OT  - HLA donor-specific antibodies
OT  - IgG subclass
OT  - transplant
EDAT- 2016/11/09 06:00
MHDA- 2016/11/09 06:01
PMCR- 2016/01/01
CRDT- 2016/11/09 06:00
PHST- 2016/07/30 00:00 [received]
PHST- 2016/10/03 00:00 [accepted]
PHST- 2016/11/09 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2016/11/09 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2016.00433 [doi]
PST - epublish
SO  - Front Immunol. 2016 Oct 24;7:433. doi: 10.3389/fimmu.2016.00433. eCollection 
      2016.